The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Capronor     (8R,9S,10R,13S,14S,17S)-13- ethyl-17...

Synonyms: Microlut, Microval, NORPLANT, Nordette, Postinor, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ovrette


Psychiatry related information on Ovrette

  • Levonorgestrel implants (Norplant) have recently been approved for use in the United States. Adolescents may be especially suited for this method of contraception because of its long duration of action and lack of dependence on patient compliance for efficacy [6].
  • The contraceptive effect of d-norgestrel given immediately after copulation in various quantities was investigated in rabbits [7].
  • No formal studies have been performed to evaluate the use of subdermal levonorgestrel implants in patients with mental retardation and physical disabilities [8].
  • The estrogen-progestin therapy group consisted of 13 women with an intact uterus, who received a simultaneous combination of a transdermal patch and a levonorgestrel (20 microg/day) intrauterine system for the same length of time [9].
  • Further trials are needed, however, to verify whether the good results observed are maintained during an entire 5-year period, to confirm the efficacy on dyspareunia and dyschezia, and to compare the effects of the levonorgestrel intrauterine device with those of other treatment options [10].

High impact information on Ovrette


Chemical compound and disease context of Ovrette


Biological context of Ovrette


Anatomical context of Ovrette


Associations of Ovrette with other chemical compounds


Gene context of Ovrette


Analytical, diagnostic and therapeutic context of Ovrette


  1. Levonorgestrel implants and intracranial hypertension. Alder, J.B., Fraunfelder, F.T., Edwards, R. N. Engl. J. Med. (1995) [Pubmed]
  2. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Hurskainen, R., Teperi, J., Rissanen, P., Aalto, A.M., Grenman, S., Kivelä, A., Kujansuu, E., Vuorma, S., Yliskoski, M., Paavonen, J. Lancet (2001) [Pubmed]
  3. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Vasilakis-Scaramozza, C., Jick, H. Lancet (2001) [Pubmed]
  4. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Kluft, C., de Maat, M.P., Heinemann, L.A., Spannagl, M., Schramm, W. Lancet (1999) [Pubmed]
  5. Myasthenia gravis and levonorgestrel implant. Brittain, J., Lange, L.S. Lancet (1995) [Pubmed]
  6. Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger. Berenson, A.B., Wiemann, C.M. Pediatrics (1993) [Pubmed]
  7. Biological, microscopic and scanning electron microscopic investigations of the effects of postinor /d-norgestrel/ in rabbits. Ugocsai, G., Resch, B., Traub, A., Sas, M. Contraception. (1984) [Pubmed]
  8. Contraceptive management for female adolescents with mental retardation and handicapping disabilities. Haefner, H.K., Elkins, T.E. Current opinion in obstetrics & gynecology. (1991) [Pubmed]
  9. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Raudaskoski, T., Tomás, C., Laatikainen, T. Acta obstetricia et gynecologica Scandinavica. (1999) [Pubmed]
  10. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Vercellini, P., Viganò, P., Somigliana, E. Current opinion in obstetrics & gynecology. (2005) [Pubmed]
  11. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. von Hertzen, H., Piaggio, G., Ding, J., Chen, J., Song, S., Bártfai, G., Ng, E., Gemzell-Danielsson, K., Oyunbileg, A., Wu, S., Cheng, W., Lüdicke, F., Pretnar-Darovec, A., Kirkman, R., Mittal, S., Khomassuridze, A., Apter, D., Peregoudov, A. Lancet (2002) [Pubmed]
  12. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Piaggio, G., von Hertzen, H., Grimes, D.A., Van Look, P.F. Lancet (1999) [Pubmed]
  13. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Jick, H., Jick, S.S., Gurewich, V., Myers, M.W., Vasilakis, C. Lancet (1995) [Pubmed]
  14. The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. Elsheikh, M., Bird, R., Casadei, B., Conway, G.S., Wass, J.A. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  15. Treatment of endometriosis in monkeys: effectiveness of continuous infusion of a gonadotropin-releasing hormone agonist compared to treatment with a progestational steroid. Mann, D.R., Collins, D.C., Smith, M.M., Kessler, M.J., Gould, K.G. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  16. Low-dose ethinylestradiol/levonorgestrel. Dando, T.M., Curran, M.P. Drugs (2005) [Pubmed]
  17. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Rosing, J., Tans, G., Nicolaes, G.A., Thomassen, M.C., van Oerle, R., van der Ploeg, P.M., Heijnen, P., Hamulyak, K., Hemker, H.C. Br. J. Haematol. (1997) [Pubmed]
  18. Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant. Piper, J.G., Follett, K.A., Fantin, A. Neurosurgery (1994) [Pubmed]
  19. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Kanarkowski, R., Tornatore, K.M., D'Ambrosio, R., Gardner, M.J., Jusko, W.J. Clin. Pharmacol. Ther. (1988) [Pubmed]
  20. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel. Elkik, F., Basdevant, A., Jackanicz, T.M., Guy-Grand, B., Mercier-Bodard, C., Conard, J., Bardin, C.W., Corvol, P. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  21. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. Gonzalo, I.T., Swerdloff, R.S., Nelson, A.L., Clevenger, B., Garcia, R., Berman, N., Wang, C. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  22. The differential effects of diestrous progestogen administration of proestrous gonadotrophin levels. Beattie, C.W., Corbin, A. Endocrinology (1975) [Pubmed]
  23. Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability. Coukell, A.J., Balfour, J.A. Drugs (1998) [Pubmed]
  24. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception. Runic, R., Schatz, F., Krey, L., Demopoulos, R., Thung, S., Wan, L., Lockwood, C.J. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  25. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Backman, T. Drug safety : an international journal of medical toxicology and drug experience. (2004) [Pubmed]
  26. Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Zhu, X., Bonet, B., Gillenwater, H., Knopp, R.H. Proc. Soc. Exp. Biol. Med. (1999) [Pubmed]
  27. Hypotriglyceridemic effects of levonorgestrel in rats. Khokha, R., Wolfe, B.M. Atherosclerosis (1984) [Pubmed]
  28. Use of low-dose oral contraceptives and stroke in young women. Schwartz, S.M., Siscovick, D.S., Longstreth, W.T., Psaty, B.M., Beverly, R.K., Raghunathan, T.E., Lin, D., Koepsell, T.D. Ann. Intern. Med. (1997) [Pubmed]
  29. Steroid ligands bind human sex hormone-binding globulin in specific orientations and produce distinct changes in protein conformation. Grishkovskaya, I., Avvakumov, G.V., Hammond, G.L., Catalano, M.G., Muller, Y.A. J. Biol. Chem. (2002) [Pubmed]
  30. Comparative study on the efficacy, acceptability, and side effects of a contraceptive pill administered by the oral and the vaginal route: an international multicenter clinical trial. Coutinho, E.M., Mascarenhas, I., de Acosta, O.M., Flores, J.G., Gu, Z.P., Ladipo, O.A., Adekunle, A.O., Otolorin, E.O., Shaaban, M.M., Abul Oyoon, M. Clin. Pharmacol. Ther. (1993) [Pubmed]
  31. Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies. Kluft, C. Current medicinal chemistry. (2000) [Pubmed]
  32. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. Pekonen, F., Nyman, T., Lähteenmäki, P., Haukkamaa, M., Rutanen, E.M. J. Clin. Endocrinol. Metab. (1992) [Pubmed]
  33. Effects of two progestins with different androgenic properties on hepatic endothelial lipase and high density lipoprotein2. Kuusi, T., Nikkilä, E.A., Tikkanen, M.J., Sipinen, S. Atherosclerosis (1985) [Pubmed]
  34. Influence of different hormonal regimens on endometrial microvascular density and VEGF expression in women suffering from breakthrough bleeding. Rogers, P.A., Martinez, F., Girling, J.E., Lederman, F., Cann, L., Farrell, E., Tresserra, F., Patel, N. Hum. Reprod. (2005) [Pubmed]
  35. The intrinsic transcriptional estrogenic activity of a non-phenolic derivative of levonorgestrel is mediated via the estrogen receptor-alpha. García-Becerra, R., Borja-Cacho, E., Cooney, A.J., Jackson, K.J., Lemus, A.E., Pérez-Palacios, G., Larrea, F. J. Steroid Biochem. Mol. Biol. (2002) [Pubmed]
  36. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Chegini, N., Rhoton-Vlasak, A., Williams, R.S. Fertil. Steril. (2003) [Pubmed]
  37. Levonorgestrel-releasing intrauterine device for the treatment of menometrorrhagia in a woman on hemodialysis. Fedele, L., Gammaro, L., Bianchi, S. N. Engl. J. Med. (1999) [Pubmed]
  38. Levonorgestrel-releasing intrauterine devices. Cohen, I. Lancet (2001) [Pubmed]
  39. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. Matthiesson, K.L., Amory, J.K., Berger, R., Ugoni, A., McLachlan, R.I., Bremner, W.J. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
WikiGenes - Universities